Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Yaryura-Tobias, B. Diamond, S. Merlis (1971)
Verbal Communication with L-Dopa TreatmentNature, 234
B. Ebert, U. Madsen, T. Lund, S. Lenz, P. Krogsgaard‐Larsen (1994)
Molecular pharmacology of the AMPA agonist, (S)-2-amino-3-(3-hydroxy-5-phenyl-4-isoxazolyl)propionic acid [(S)-APPA] and the AMPA antagonist, (R)-APPANeurochemistry International, 24
D. Kammen, M. Kelley (1991)
Dopamine and norepinephrine activity in schizophrenia An intergrative perspectiveSchizophrenia Research, 4
Y. Misu, Y. Goshima, H. Ueda, H. Okamura (1996)
NEUROBIOLOGY OF l-DOPAergic SYSTEMSProgress in Neurobiology, 49
K. Inanaga, M. Oshima, H. Tachibana, K. Nakamura, K. Koketsu (1971)
Three cases of schizophrenia treated with L-dopa.The Kurume medical journal, 18 3
J. Callicott, Alessandro Bertolino, M. Egan, V. Mattay, F. Langheim, Daniel Weinberger (2000)
Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia.The American journal of psychiatry, 157 10
J. Opacka‐Juffry, D. Brooks (1995)
L‐Dihydroxyphenylalanine and its decarboxylase: New ideas on their neuroregulatory rolesMovement Disorders, 10
K. Burris, T. Molski, Cen Xu, Elaine Ryan, K. Tottori, T. Kikuchi, F. Yocca, P. Molinoff (2002)
Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 ReceptorsJournal of Pharmacology and Experimental Therapeutics, 302
S. Kapur, G. Remington (2001)
Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficientBiological Psychiatry, 50
J. Cedarbaum (1987)
Clinical Pharmacokinetics of Anti-Parkinsonian DrugsClinical Pharmacokinetics, 13
H. Meltzer, J. Kennedy, Jin Dai, M. Parsa, D. Riley (1995)
Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: A high potency effect of clozapineNeuropsychopharmacology, 12
H. Hoffmann, Z. Kupper, M. Zbinden, H. Hirsbrunner (2003)
Predicting vocational functioning and outcome in schizophrenia outpatients attending a vocational rehabilitation programSocial Psychiatry and Psychiatric Epidemiology, 38
K. Inanaga, M. Ohshima, T. Nagata, I. Yamauchi (1975)
Behavioral Effects of L‐Dopa and Thyrotropin‐Releasing Hormone in Schizophrenic Patients: A Preliminary ReportPsychiatry and Clinical Neurosciences, 29
F. White, R. Wang (1983)
Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat.Life sciences, 32 9
C. Tamminga, A. Carlsson (2002)
Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis.Current drug targets. CNS and neurological disorders, 1 2
R. Trosch, Joseph Friedman, M. Lannon, R. Pahwa, Diane Smith, L. Seeberger, Christopher O'Brien, P. LeWitt, W. Koller (1998)
Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experienceMovement Disorders, 13
J. Mendels, J. Stinnett, D. Burns, A. Frazer (1975)
Amine precursors and depression.Archives of general psychiatry, 32 1
M. Davidson, R. Keefe, R. Mohs, L. Siever, M. Losonczy, T. Horvath, K. Davis (1987)
L-dopa challenge and relapse in schizophrenia.The American journal of psychiatry, 144 7
M. Gutiérrez, M. Alpert, J. Guimón, A. Friedhoff, V. Veramendi (1979)
[Controlled study on the possibilities of L-dopa in the residual extrapyramidal syndrome caused by neuroleptics].Actas luso-espanolas de neurologia, psiquiatria y ciencias afines, 7 3
Michael Green, R. Kern, D. Braff, J. Mintz (2000)
Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?Schizophrenia bulletin, 26 1
A. Grace (1991)
Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophreniaNeuroscience, 41
M. Akil, J. Pierri, R. Whitehead, C. Edgar, C. Mohila, A. Sampson, D. Lewis (1999)
Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects.The American journal of psychiatry, 156 10
G. Chouinard, B. Jones (1980)
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.The American journal of psychiatry, 137 1
H. Hall, G. Sedvall, O. Magnusson, J. Kopp, C. Halldin, L. Farde (1994)
Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human BrainNeuropsychopharmacology, 11
T. Kato, N. Karai, M. Katsuyama, M. Nakamura, J. Katsube (1987)
Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain. Comparison with that of L-dopa.Biochemical pharmacology, 36 18
B. Angrist, G. Sathananthan, S. Gershon (1973)
Behavioral effects of l-Dopa in schizophrenic patientsPsychopharmacologia, 31
J. Reith, C. Benkelfat, A. Sherwin, Y. Yasuhara, H. Kuwabara, F. Andermann, S. Bachneff, P. Cumming, M. Diksic, S. Dyve, P. Étienne, Alan Evans, S. Lal, M. Shevell, G. Savard, D. Wong, G. Chouinard, A. Gjedde (1994)
Elevated dopa decarboxylase activity in living brain of patients with psychosis.Proceedings of the National Academy of Sciences of the United States of America, 91 24
Yaryura-Tobias Ja, A. Wolpert, L. Dana, S. Merlis (1970)
Action of L-Dopa in drug induced extrapyramidalism.Diseases of the nervous system, 31 1
H. Meltzer (1992)
Treatment of the neuroleptic-nonresponsive schizophrenic patient.Schizophrenia bulletin, 18 3
D. Loeffler, P. LeWitt, P. Juneau, D. Camp, L. Arnold, K. Hyland (1998)
Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidationBrain Research Bulletin, 47
A. Breier, T. Su, R. Saunders, R. Carson, B. Kolachana, A. Bartolomeis, D. Weinberger, N. Weisenfeld, A. Malhotra, W. Eckelman, D. Pickar (1997)
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.Proceedings of the National Academy of Sciences of the United States of America, 94 6
C. Ogura, A. Kishimoto, T. Nakao (1976)
Clinical effect of L-dopa on schizophrenia.Current therapeutic research, clinical and experimental, 20 3
J. Gerlach, K. Lühdorf (1975)
The effect of l-dopa on young patients with simple schizophrenia, treated with neuroleptic drugsPsychopharmacologia, 44
J. Tedroff, S. Aquilonius, P. Hartvig, H. Lundqvist, P. Bjurling, B. Långström (1992)
Estimation of regional cerebral utilization of [11C]‐L‐3, 4‐dihydroxy‐phenylalanine (DOPA) in the primate by positron emission tomographyActa Neurologica Scandinavica, 85
J. Friedman, D. Adler, K. Davis (1999)
The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's diseaseBiological Psychiatry, 46
G. Chouinard, L. Annable, P. Mercier, L. Turnier (1987)
Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms.Psychopharmacology bulletin, 23 1
J. Gold, R. Goldberg, S. McNary, L. Dixon, A. Lehman (2002)
Cognitive correlates of job tenure among patients with severe mental illness.The American journal of psychiatry, 159 8
S. Kapur, P. Seeman (2001)
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.The American journal of psychiatry, 158 3
Gilberti Pl, M. Harris, L. Mcadams, D. Jeste, R. Baldessarini, A. Viguera, W. Carpenter, C. Tamminga, J. Greden, R. Tandon, H. Meltzer, K. Nuechterlein, M. Gitlin, K. Subotnik, R. Wyatt (1995)
Neuroleptic withdrawal in schizophrenic patients. A review of the literature.Archives of general psychiatry, 52 3
N. Buu (1989)
Vesicular accumulation of dopamine following L-DOPA administration.Biochemical pharmacology, 38 11
M. Alpert, Friedhoff Aj, Marcos Lr, F. Diamond (1978)
Paradoxical reaction to L-dopa in schizophrenic patients.The American journal of psychiatry, 135 11
A. Abi-Dargham, J. Rodenhiser, D. Printz, Y. Zea‐Ponce, R. Gil, L. Kegeles, R. Weiss, T. Cooper, J. Mann, R. Heertum, J. Gorman, M. Laruelle (2000)
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.Proceedings of the National Academy of Sciences of the United States of America, 97 14
M. Laruelle, A. Abi-Dargham (1999)
Dopamine as the wind of the psychotic fire: new evidence from brain imaging studiesJournal of Psychopharmacology, 13
D. Oren, D. Moul, P. Schwartz, Thomas Wehr, Norman Rosenthal (1994)
A controlled trial of levodopa plus carbidopa in the treatment of winter seasonal affective disorder: a test of the dopamine hypothesis.Journal of clinical psychopharmacology, 14 3
F. Buchanan, R. Parton, J. Warren, E. Baker (1975)
Double Blind Trial of L-Dopa in Chronic Schizophrenia*Australian and New Zealand Journal of Psychiatry, 9
W. Bunney, H. Brodie, D. Murphy, F. Goodwin (1971)
Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania.The American journal of psychiatry, 127 7
F. Yokoi, G. Gründer, K. Bizière, M. Stephane, A. Doğan, R. Dannals, H. Ravert, A. Suri, S. Bramer, D. Wong (2002)
Erratum: Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride⋆Neuropsychopharmacology, 27
J. Tedroff (1997)
The Neuroregulatory Properties of L-DOPA. A Review of the Evidence and Potential Role in the Treatment of Parkinson's DiseaseReviews in the Neurosciences, 8
H. Calil, J. Yesavage, L. Hollister (1977)
Low dose levodopa in schizophrenia.Communications in psychopharmacology, 1 6
A. Abi-Dargham, O. Mawlawi, I. Lombardo, R. Gil, D. Martínez, Yiyun Huang, D. Hwang, J. Keilp, L. Kochan, R. Heertum, J. Gorman, M. Laruelle (2002)
Prefrontal Dopamine D1 Receptors and Working Memory in SchizophreniaThe Journal of Neuroscience, 22
H. Meltzer, Alison Sommers, D. Luchins (1986)
The Effect of Neuroleptics and Other Psychotropic Drugs on Negative Symptoms in SchizophreniaJournal of Clinical Psychopharmacology, 6
P. Seeman, T. Tallerico (1998)
Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptorsMolecular Psychiatry, 3
O. Wolkowitz (1993)
Rational polypharmacy in schizophrenia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 5 2
R. Baldessarini, A. Viguera, G. Faedda, D. Garver, T. Suppes, L. Tondo, D. Kammen, R. Wyatt, D. Gardner (1995)
Neuroleptic withdrawal in schizophrenic patients.Archives of general psychiatry, 52 3
K. Inanaga, Y. Nakazawa, Katsumi Inoue, H. Tachibana, M. Oshima, T. Kotorii, Masatoshi Tanaka, N. Ogawa (1975)
Double‐Blind Controlled Study of L‐Dopa Therapy in SchizophreniaPsychiatry and Clinical Neurosciences, 29
R. Carey, M. Pinheiro-Carrera, H. Dai, C. Tomaz, J. Huston (1995)
l-DOPA and psychosis: Evidence for l-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosteroneBiological Psychiatry, 38
H. Fernandez, J. Friedman, C. Jacques, M. Rosenfeld (1999)
Quetiapine for the treatment of drug‐induced psychosis in Parkinson's diseaseMovement Disorders, 14
S. Kay, L. Opler (1986)
L-DOPA in the Treatment of Negative Schizophrenic Symptoms: A Single-Subject Experimental StudyThe International Journal of Psychiatry in Medicine, 15
W. Perlstein, C. Carter, D. Noll, J. Cohen (2001)
Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia.The American journal of psychiatry, 158 7
M. Yamauchi (1976)
Effects of L‐Dopa and Vitamin B6 on Electroencephalograms of Schizophrenic Patients: A Preliminary ReportPsychiatry and Clinical Neurosciences, 30
W. Turner, S. Merlis (1964)
A CLINICAL TRIAL OF PARGYLINE AND DOPA IN PSYCHOTIC SUBJECTS.Diseases of the nervous system, 25
N. Andreasen (1985)
Negative syndrome in schizophrenia: strategies for long-term management.Advances in biochemical psychopharmacology, 40
F. Brambilla, S. Scarone, M. Ponzano, C. Maffei, P. Nobile, C. Rovère, A. Guastalla (1979)
Catecholaminergic drugs in chronic schizophrenia.Neuropsychobiology, 5 4
O. Benkert, F. Müller-Siecheneder, H. Wetzel (1995)
Dopamine agonists in schizophrenia: a reviewEuropean Neuropsychopharmacology, 5
K. Berman, D. Weinberger (1990)
The prefrontal cortex in schizophrenia and other neuropsychiatric diseases: in vivo physiological correlates of cognitive deficits.Progress in brain research, 85
P. Cumming, H. Kuwabara, A. Ase, A. Gjedde (1995)
Regulation of DOPA Decarboxylase Activity in Brain of Living RatJournal of Neurochemistry, 65
S. Matthysse, E. Smith, T. Puck, G. Edelman (1972)
Prospects for research on schizophrenia. VI. Biochemical hypotheses and new techniques.Neurosciences Research Program bulletin, 10 4
Jack Ludatscher (1989)
Stable remission of tardive dyskinesia by L-dopa.Journal of clinical psychopharmacology, 9 1
R. Rosenthal, R. Rosnow (1984)
Essentials of Behavioral Research: Methods and Data Analysis
P. Fleming, H. Makar, K. Hunter (1970)
Levodopa in drug-induced extrapyramidal disorders.Lancet, 2 7684
V. Beramendi, M. Alpert, J. Guimón, A. Friedhoff, M. Gutiérrez (1980)
[Controlled study of L-dopa in schizophrenia with reference to the theory of hypersensitivity of dopamine receptors].Archivos de neurobiologia, 43 2
L. Chiodo, B. Bunney (1983)
Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons, 3
F. Yokoi, G. Gründer, K. Bizière, M. Stephane, A. Doğan, R. Dannals, H. Ravert, A. Suri, S. Bramer, D. Wong (2002)
Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]RacloprideNeuropsychopharmacology, 27
B. Kolachana, R. Saunders, D. Weinberger (1995)
Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: Anin vivo neurochemical assessment in the rhesus monkeyNeuroscience, 69
Jianping Chen, D. Ruan, W. Paredes, E. Gardner (1992)
Effects of acute and chronic clozapine on dopaminergic function in medial prefrontal cortex of awake, freely moving ratsBrain Research, 571
G. Sathananthan, B. Angrist, S. Gershon (1973)
Response threshold to levodopa in psychiatric patients.Biological psychiatry, 7 2
L. Hedges, I. Olkin (1987)
Statistical Methods for Meta-Analysis
A. Dolphin, P. Jenner, C. Marsden (1976)
Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activityPharmacology Biochemistry and Behavior, 5
J. Yaryura-Tobias, B. Diamond, S. Merlis (1970)
The action of L-dopa on schizophrenic patients (a preliminary report).Current therapeutic research, clinical and experimental, 12 8
M. Chakos, J. Lieberman, E. Hoffman, D. Bradford, B. Sheitman (2001)
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.The American journal of psychiatry, 158 4
Y. Kai (1976)
The Effect of L‐Dopa and Vitamin Bs in SchizophreniaPsychiatry and Clinical Neurosciences, 30
Dunner Dl, Fieve Rr (1975)
Affective disorder: studies with amine precursors.American Journal of Psychiatry, 132
K. Inanaga, Katsumi Inoue, H. Tachibana, M. Oshima, T. Kotorii (1972)
Effect of L‐Dopa in SchizophreniaPsychiatry and Clinical Neurosciences, 26
P. Cumming, A. Ase, C. Laliberté, H. Kuwabara, A. Gjedde (1997)
In Vivo Regulation of DOPA Decarboxylase by Dopamine Receptors in Rat BrainJournal of Cerebral Blood Flow & Metabolism, 17
P. Garfinkel, H. Stancer (1976)
L-Dopa and SchizophreniaThe Canadian Journal of Psychiatry, 21
J. Tedroff, M. Pedersen, S. Aquilonius, P. Hartvig, Gunilla Jacobsson, Bengt Långström (1996)
Levodopa‐induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PETNeurology, 46
K. Shingu, I. Kawai, Koichi Yamada (1979)
Three Cases of Unipolar Delusional Depression Responsive to L‐DopaPsychiatry and Clinical Neurosciences, 33
Anthony Grace (2005)
Cortical regulation of subcortical dopamine systems and its possible relevance to schizophreniaJournal of Neural Transmission / General Section JNT, 91
H. Meltzer, J. Kennedy, Jin Dai, M. Parsa, D. Riley (1995)
Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's DiseaseNeuropsychopharmacology, 12
L. Lindström, O. Gefvert, G. Hagberg, T. Lundberg, M. Bergström, P. Hartvig, B. Långström (1999)
Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(β-11C) DOPA and PETBiological Psychiatry, 46
T. Nguyen, M. Angers (1987)
Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain.Biochemical pharmacology, 36 10
In patients already on antipsychotic drugs, the addition of l -dopa can be beneficial. Dopamine agonists merit further consideration as adjuncts to antipsychotic drugs in the treatment of schizophrenia.
Psychopharmacology – Springer Journals
Published: Feb 1, 2004
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.